Source Count: 0 | Weighted Score: 0 | Source Confidence: [1/5] | Primary Tier: 1–2 | Last Updated: March 10, 2026
Keywords: genetic engineering, CRISPR, gene editing, designer babies, eugenics, germline editing, gene therapy, He Jiankui, GMO, transhumanism, genetic enhancement, disability rights, informed consent, precautionary principle, somatic vs germline, Asilomar, biosafety
Category Tags: ethics, genetics, biotechnology, medicine, bioethics
Cross-References: ZE_3_02 — Bioethics · Z_4_05 — Synthetic Biology · L_4_06 — Epigenetics · S_5_03 — Gene Therapy

QUICK SUMMARY

The ethics of genetic engineering confronts humanity's growing capacity to alter the genetic code of organisms — including humans — raising questions about the limits of technological intervention in nature, the distinction between therapy and enhancement, the specter of eugenics, and intergenerational justice. CRISPR-Cas9 (Jennifer Doudna & Emmanuelle Charpentier, 2012 — Nobel Prize in Chemistry, 2020) dramatically lowered the cost, complexity, and precision of gene editing, making genetic modification accessible to laboratories worldwide and accelerating ethical urgency. The He Jiankui case (November 2018): Chinese biophysicist He Jiankui announced the birth of twin girls ("Lulu and Nana") whose embryos he had edited using CRISPR to disable the CCR5 gene (intended to confer HIV resistance) — the first known germline-edited human births. The scientific community condemned the experiment: it was medically unnecessary (safer HIV prevention exists), the editing was imprecise (mosaicism detected), informed consent was inadequate, and germline edits are heritable — potentially affecting all descendants. He was sentenced to three years in prison (December 2019). Key ethical distinctions: (1) Somatic vs. germline editing: somatic gene therapy (editing cells in a living patient — e.g., sickle cell disease treatments using CRISPR, approved 2023) affects only the individual; germline editing (altering eggs, sperm, or embryos) creates heritable changes affecting future generations who cannot consent — most scientific bodies (National Academies, 2017; WHO, 2021) recommend against clinical germline editing at present; (2) Therapy vs. enhancement: treating genetic disease (cystic fibrosis, Huntington's) is widely accepted; enhancing traits (intelligence, height, athletic ability) raises concerns about creating genetic "haves" and "have-nots" — Michael Sandel (The Case against Perfection, 2007) argues enhancement expresses a "hyperagency" that corrodes appreciation for the "giftedness" of life. Eugenics — the historical program of "improving" human populations through selective breeding — resulted in forced sterilization programs (US: >60,000 sterilized, 1907–1979; Nazi Germany: ~400,000 sterilized, ~200,000 killed in Aktion T4) and is invoked as a cautionary precedent for genetic engineering: critics warn that genetic selection could constitute a "new eugenics" — privatized, consumer-driven, but reproducing social biases about disability, race, and "desirable" traits. Disability rights perspectives (Adrienne Asch, Rosemarie Garland-Thomson) argue that genetic selection against disabilities expresses and reinforces ableist assumptions — the problem is not genetic variation but a society that fails to accommodate it.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Scholarly Consensus)

1.1 He Jiankui Case

• He Jiankui's germline editing of human embryos (2018) was confirmed by scientific investigation and his own presentations; the experiment was universally condemned by scientific organizations for violating informed consent, medical necessity, and safety standards; he was convicted and imprisoned in China (2019)

1.2 CRISPR-Cas9 as Gene Editing Tool

• CRISPR-Cas9 was adapted for genome editing by Doudna & Charpentier (published June 2012, Science); it enables targeted DNA modification with unprecedented precision, though off-target effects remain a concern; the tool has been applied across agriculture, medicine, and basic research, and the first CRISPR-based therapy (Casgevy, for sickle cell disease) was approved by the UK MHRA and US FDA in 2023

1.3 Historical Eugenics Programs

• Eugenics programs in the US (Buck v. Bell, 1927 — Supreme Court upheld compulsory sterilization; >60,000 sterilized across 32 states), Nazi Germany (Aktion T4 euthanasia program), and Scandinavia (Sweden sterilized ~63,000 people, 1934–1976) are extensively documented — they demonstrate the dangers of state-directed programs to control reproduction based on assumptions about genetic "fitness"

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Therapy-Enhancement Distinction

• Whether a principled line can be drawn between genetic therapy (correcting diseases) and genetic enhancement (improving normal function) is debated: Julian Savulescu argues parents have a moral obligation to select the "best" children possible ("procreative beneficence"); Sandel (2007) and Habermas (The Future of Human Nature, 2003) argue enhancement undermines autonomy and equality — the distinction may be fuzzy in practice (e.g., is correcting a gene associated with lower intelligence therapy or enhancement?)

2.2 Precautionary Principle

• The Asilomar Conference (1975) established a precedent for scientific self-regulation in genetics, with researchers voluntarily pausing recombinant DNA research until safety guidelines were developed; whether similar moratoriums on germline editing (called for by Lander et al., Nature, 2019) can effectively govern a globally distributed technology is uncertain

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Genetic Enhancement and Inequality

• Some predict that if genetic enhancement becomes available, it will be accessible only to the wealthy, creating a biologically stratified society ("Gattaca scenario") — while plausible, the timeline and feasibility of complex trait enhancement (intelligence involves thousands of genes with small effects) make this more distant than often assumed

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Designer Babies Are Imminent

• DEBUNKED Media narratives suggesting "designer babies" — children with custom-selected traits for intelligence, appearance, and personality — are imminent misrepresent the science; complex traits are polygenic (involving hundreds or thousands of genes with small, interacting effects), gene-environment interactions are poorly understood, and current technology cannot reliably engineer such traits; single-gene disease prevention is feasible, but "building to order" is not

Counter-Arguments

• Restricting genetic technology may perpetuate avoidable suffering — parents who could prevent their children from inheriting Huntington's disease, cystic fibrosis, or sickle cell disease have strong moral reasons to use available technology
• The eugenics analogy may be overstated — historical eugenics was state-coerced and based on pseudoscience; modern genetic medicine is (ideally) voluntary, informed, and evidence-based
• Disability rights arguments, while important, should not override individual reproductive autonomy — prospective parents, not disability advocates, should decide whether to use genetic technology

IMAGES

No images assigned yet.

BIBLIOGRAPHY

• Doudna, J.A. & Sternberg, S.H. A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution. Houghton Mifflin Harcourt (2017). DOI: 10.1096/fj.181202ufm
• Sandel, M.J. The Case against Perfection: Ethics in the Age of Genetic Engineering. Harvard UP (2007). DOI: 10.4159/9780674043060
• National Academies of Sciences. Human Genome Editing: Science, Ethics, and Governance. National Academies Press (2017). DOI: 10.17226/24623
• Habermas, J. The Future of Human Nature. Trans. W. Rehg et al. Polity (2003).
• Kevles, D.J. In the Name of Eugenics. Harvard UP (1995).
• Savulescu, J. "Procreative Beneficence." Bioethics 15 (2001): 413–426. DOI: 10.1111/1467-8519.00251
• Lander, E.S. et al. "Adopt a Moratorium on Heritable Genome Editing." Nature 567 (2019): 165–168. DOI: 10.1038/d41586-019-00726-5.
• Garland-Thomson, R. "The Case for Conserving Disability." J. Bioethical Inquiry 9 (2012): 339–355.
• Regalado, A. "EXCLUSIVE: Chinese Scientists Are Creating CRISPR Babies." MIT Technology Review (Nov. 25, 2018).
• WHO Expert Advisory Committee. Human Genome Editing: Recommendations. WHO (2021).
• Buchanan, A. et al. From Chance to Choice: Genetics and Justice. Cambridge UP (2000).
• Berg, P. et al. "Asilomar Conference on Recombinant DNA Molecules." Science 188 (1975): 991–994.
• Emmanuelle Charpentier and Jennifer A. Doudna. WORLD SCIENTIFIC, 2024. DOI: 10.1142/9789811260582_0005

CROSS-REFERENCE INDEX

Last Updated: March 10, 2026

Corrections

• Document header date — restored to March 10, 2026. The header read 2026-03-13 10, 2026: an ISO date had been written over the month name, leaving the day and year. Recovered from this document's own footer line, which preserves March 10, 2026 and whose day and year already agreed with the header remnant. No date was guessed. Corpus hygiene campaign, Phase 4, 2026-07-29.